secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001437749-25-013334
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development
------------------------------------------------------------------------------

- Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.
- He previously served as VP and Therapeutic Area Head for Inflammation at Gilead Sciences.
- Company plans to start Phase 2 proof-of-concept trial in IPF in H2 2025.
- Received time-based option for 260,000 shares vesting over 42 months and performance-based option for 26,000 shares.
- Grants are inducement awards under Nasdaq Listing Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/0001437749-25-013334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/cont20250422_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer